Revised. Amendments from Version 1
==================================

Following the reviewers' comments, this revised version of the manuscript now includes additional *in silico *sequence analysis assessing identified antibody cross-reactivities. The results and conclusion sections are now addressing the additional findings. A new Table 5 and Supplementary Table S1 have been added showing results for all possible two-pair sequence alignment combinations presented as BLAST scores, SIM scores and E-values.

Introduction
============

Secondary label-conjugated and non-conjugated detection antibodies are frequently used in a wide range of research applications. However, they are often affinity-isolated, polyclonal reagents that may lack the highest standard of antibody validation. The antibodies characterised in this study are a polyclonal anti-chicken IgY antibody produced in rabbit (31104, Thermo Fisher) and a polyclonal goat anti-rabbit IgG antibody conjugated with alkaline phosphatase (AP) (A3687, Sigma-Aldrich). Although the use of the rabbit anti-IgY antibody in the literature is limited, the goat anti-rabbit IgG AP has been extensively utilised for over 15 years ^[@ref-1],\ [@ref-2]^.

The research conducted in this laboratory examines complex antibody repertoires in humans and animals by means of protein arrays. Protein arrays are frequently used to profile antibody binding to human proteins in autoimmune disease ^[@ref-3]^, cancer ^[@ref-4]^ and in healthy individuals ^[@ref-5]^. Other protein array applications include recombinant ^[@ref-6]^ and hybridoma-derived ^[@ref-7]^ antibody characterisation studies. This article investigates the cross-reactivity of a rabbit anti-chicken IgY and an alkaline phosphatase-conjugated goat anti-rabbit IgG, which were used for the profiling of IgY antibody responses to human antigens in chickens immunised with human cancer cells. The protein array technology applied here, developed by Büssow and colleagues ^[@ref-8]^, is comprised in its current version of a fully annotated set of 7,390 distinct human proteins, that may serve as potential antigens. The aim of this study is to define a cross-reactivity reference list for the two described secondary antibodies, which can then be used to eliminate non-specific binders from ongoing chicken IgY profiling studies. Furthermore, publication of the cross-reactivity reference list provides a valuable resource of potential false-positive binders to researchers using the same antibodies. may support other researchers using these antibodies in the evaluation of their experiments.

Materials and methods
=====================

Antibody details
----------------

Rabbit anti-chicken IgY (H+L) secondary antibody (Thermo Fisher Scientific, Product number 31104, Lot code PK19380211) is a polyclonal antibody that targets the variable heavy and light chains of chicken IgY immunoglobulins ( [Table 1](#T1){ref-type="table"}). The antibody was isolated from the serum of the antigen-immunised rabbit through immunoaffinity chromatography using antigen coupled to agarose beads. The antibody was added to the protein array at a 1/1,000 dilution in 2% (w/v) bovine serum albumin (BSA, Sigma-Aldrich, A2153) in tris-buffered saline (TBS, Trizma ^®^ Base, Sigma-Aldrich, T6066 and sodium chloride, Fisher Scientific, S/3160/68) with 0.1%, v/v, Tween 20 (Sigma-Aldrich, P1379).

###### Details of characterised antibodies.

  -----------------------------------------------------------------------------------------------------------------
  Antibody                         Manufacturer               Catalogue\   Lot Number   Stock\          RRID
                                                              Number                    Concentration   
  -------------------------------- -------------------------- ------------ ------------ --------------- -----------
  Rabbit anti-Chicken IgY (H+L)    Thermo Fisher Scientific   31104        PK19380211   2.3 mg/mL       AB_228382

  Goat anti-rabbit IgG Alkaline\   Sigma-Aldrich              A3687        SLBJ6146V    4.0 mg/mL       AB_258103
  Phosphatase conjugated                                                                                
  -----------------------------------------------------------------------------------------------------------------

Alkaline phosphatase-conjugated goat anti-rabbit IgG (whole molecule) (Sigma-Aldrich, Product number A3687, Lot code SLBJ6146V) is a polyclonal antibody that targets all rabbit IgGs ( [Table 1](#T1){ref-type="table"}). The antibody was isolated through immunospecific purification of antisera from a rabbit IgG-immunised goat. Following isolation, the anti-rabbit IgG was conjugated to alkaline phosphatase using glutaraldehyde-based cross-linkage. The antibody was added to the protein array at a 1/1,000 dilution in 2% (w/v) BSA in tris-buffered saline (TBS) with 0.1%, v/v, Tween 20.

Protein arrays
--------------

Unipex protein arrays were obtained from Source Bioscience Life Sciences (Nottingham, UK). The Unipex arrays comprise of 15,300 fully annotated *E. coli* clones expressing a total of 7,390 distinct in-frame ORF human recombinant proteins. The Unipex proteins are immobilized under denaturing conditions directly on the PVDF membrane surfaces exposing linear sequence epitopes ideally suited for epitope mapping, antibody profiling and antibody cross-reactivity analyses. The details of protein arrays utilised in this study are provided in [Table 2](#T2){ref-type="table"}. For general information on Unipex protein arrays please refer to: ( <http://www.lifesciences.sourcebioscience.com/media/290406/sbs_ig_manual_proteinarray_v1.pdf>).

###### Details of protein arrays.

  Protein array   Library Number   Array Number   Manufacturer
  --------------- ---------------- -------------- -------------------
  Unipex 1 pt.1   9027             633.4.730      Source Bioscience
  Unipex 2 pt.1   9028             634.5.737      Source Bioscience

Cross-reactivity assessment
---------------------------

Antibody cross-reactivity was assessed using Unipex protein arrays. The detailed experimental protocol is provided in [Table 3](#T3){ref-type="table"}. Briefly, secondary rabbit anti-chicken IgY and goat anti-rabbit IgG AP were validated in preparation for a chicken IgY antibody profiling experiment of a chicken immunised with human cancer cells. Protein arrays were probed with secondary antibodies in the absence of IgY-containing chicken serum, as described in [Table 3](#T3){ref-type="table"}. Signal generation for array-bound secondary antibodies was obtained using AttoPhos AP fluorescent substrate system (Promega, S1001) diluted 1 in 8 in AP buffer (1mM MgCl2, Sigma-Aldrich, M4880 and 100mM Tris base, pH 9.5). Protein array image acquisition was conducted using a Fuji scanner Fla5100. Positive signals were localized according to the manufacturer's protocol. Briefly, array proteins were spotted in duplicate in a 3×3 square pattern. The centre spot of each square being a guide dot surrounded by eight flanking protein spots. Each protein was spotted around the navigation dot in one of four predetermined patterns (see [Figure 1b](#f1){ref-type="fig"}). Varying background intensities were controlled by adjusting brightness and contrast of the image using Visual Grid software (GPC Biotech) to allow best possible scoring conditions. The degree of signal intensity was evaluated for each protein pair with the value 1 corresponding to a weak signal, value 2 corresponding to a moderate signal and value 3 corresponding to a strong signal. The x- y- coordinates of each positive pattern were merged with the Unipex protein database provided by the manufacturer (Source Bioscience) resulting in identification of GenBank and UniGene ID's for each positive signal. This is a commonly used method for scoring signal intensities as previously shown by this group ^[@ref-4]^ and others ^[@ref-9],\ [@ref-10]^. Protein annotations were retrieved from the Unipex database provided by the manufacturer and updated using the National Cancer Institute's UniGene CGAP Gene Finder tool ( <http://cgap.nci.nih.gov/Genes/GeneFinder>).

###### Secondary antibody protein array analysis protocol.

  -------------------------------------------------------------------------------------------------------------------------
  Protocol steps                    Objective                         Reagent                                 Time
  --------------------------------- --------------------------------- --------------------------------------- -------------
  Protein array\                    Rinse array                       70% (v/v) ethanol                       5 min
  preparation                                                                                                 

  Remove ethanol and rinse          dH ~2~0 for 2                     2 min                                   

  Wipe off all *E. coli* colonies   laminar tissue                    As appropriate                          

  Wash 1                            Wash off any *E. coli* debris     TBST-T                                  10min (x3)

  TBS                               2min (x2)                                                                 

  TBS                               10 min                                                                    

  Array blocking                    Block arrays by shaking           5% (w/v) Milk Marvel TBS-T              2h

  Wash 2                            Wash off any Blocking solution    TBS-T                                   15min (x3)

  Incubate first\                   Rabbit anti-chicken IgY           1 in 1,000 (no recommended\             2h
  antibody                                                            western dil.) in 2% (w/v) BSA TBS-T     

  Wash 2                            Wash off any unbound antibody     TBS-T                                   15 min (x3)

  Incubate second\                  Goat anti-rabbit IgG-AP           1 in 1,000 in 2% (w/v) BSA TBS-T        2h
  antibody                                                                                                    

  Wash 3                            Wash off any unbound antibody     TBS-T                                   10 min (x2)

  TBS                               10 min (x2)                                                               

  Protein array signal\             Signal generation for array\      AttoPhos AP Fluorescent Substrate\      10 min
  detection                         bound goat anti-rabbit IgG-AP     diluted 1 in 8 in AP buffer (1mM\       
                                                                      MgCl ~2~, 100mM Tris base, pH 9.5)      

                                    Protein array image acquisition   FujiScanner Fla5100 (Settings Laser:\   18 min
                                                                      473, Filter: LPB, Resolution 50μm       
  -------------------------------------------------------------------------------------------------------------------------

Epitope analysis
----------------

To investigate whether antibody binding to protein arrays was due to epitope similarities between the animal immunogens used to produce the secondary antibodies and the human proteins on the arrays we performed a comparative analysis as follows. Sequences of human antigens on the array bound by the secondary antibodies were obtained from the PubMed website ( <http://www.ncbi.nlm.nih.gov/protein/>) using IDs present in the Unipex protein database and compared to chicken immunoglobulin proteins \[Ig lambda chain C region (NCBI Accession: P20763.1), Ig lambda chain V-1 region (NCBI Accession: P04210.1), immunoglobulin Y heavy chain constant region (NCBI Accession: XP_015130394.1) and immunoglobulin Y heavy chain variable region (NCBI Accession: ADF29959.1)\], as well as to rabbit immunoglobulin proteins \[Ig gamma chain C region (UniProtKB: P01870), immunoglobulin heavy chain VDJ region, partial (NCBI Accession: AAA51320.1), Ig lambda chain C region (UniProtKB: P01847.2) and Ig lambda chain variable region, partial (NCBI Accession: AAA31364.1)\]. For antigen similarity comparisons, sequence similarities were analysed using BLAST. Non-intersecting protein sequence alignments were analysed using the local similarity program SIM adjusted to the BLOSUM62 comparison matrix to ensure amino acid complementarity of linear B-cell epitopes as previously shown ^[@ref-11]^. The threshold for sequence similarity was set to BLAST E-values below 1 × 10 ^-10^ and SIM score values above 50.

Results
=======

Probing protein arrays with antibodies allows the assessment of their specificity and cross-reactivity across a large numbers of potential antigens in parallel ^[@ref-12],\ [@ref-13]^. Here we investigated the cross-reactivity of a secondary rabbit anti-chicken IgY and a goat anti-rabbit IgG labelled with AP, using a single set of human protein arrays in the absence of chicken serum. We identified a total of 63 binding events, of which 61 corresponded to unique proteins ( [Table 4](#T4){ref-type="table"}). The identified positive signals varied in strength, as shown in [Figure 1](#f1){ref-type="fig"}, with intensity 3 being the strongest and 1 the weakest. Five of the identified signals were scored as intensity 3, twelve signals were scored as intensity 2 and remainder scored as intensity 1. The original protein array images are shown in [Figure S1](#FS1){ref-type="other"} and [Figure S2](#FS2){ref-type="other"} ( [Supplementary material](#SM1){ref-type="other"}) and protein array images with highlighted positive signals, which correspond the cross-reactive proteins listed in [Table 4](#T4){ref-type="table"}, are shown in [Figure S3](#FS3){ref-type="other"} and [Figure S4](#FS4){ref-type="other"} ( [Supplementary material](#SM1){ref-type="other"}).

![Cross-reactivity of rabbit anti-chicken IgY and goat anti-rabbit IgG identified by protein array screening.\
( **A**) Image of a whole protein array and a representative section illustrating antibody-antigen binding at three different signal intensities; 3 = strong, 2 = intermediate and 1 = weak. ( **B**) The proteins are arranged in a 3×3 pattern on the array and all proteins are arrayed twice and appear as duplicate spots in a particular pattern within a block after a successful hybridization. ( **C**) Description of proteins chosen as examples provided on the representative array image above; signal intensities, patterns, Unigene IDs and protein names are listed.](f1000research-5-12612-g0000){#f1}

###### Reference list of antibody cross-reactivity identified by protein array analysis.

  -----------------------------------------------------------------------------------------------------------------
  Protein array\    Signal\          GenBankID      UnigeneID   Name
  clone ID          Intensity ^\*^                              
  ----------------- ---------------- -------------- ----------- ---------------------------------------------------
  IMGSp9028F0610D   3                BM914329       Hs.533963   Clone SFV019_2F05H immunoglobulin heavy\
                                                                chain variable region

  IMGSp9028H079D    3                BQ711793       Hs.547404   Clone IgA-MZ-aa42c-2 immunoglobulin alpha\
                                                                heavy chain variable region (IgA)

  IMGSp9028F0316D   3                BQ709082       Hs.620437   IGH mRNA for immunoglobulin heavy chain\
                                                                VHDJ region, partial cds, clone:TRH1-16

  IMGSp9028G0921D   3                BX417981       Hs.698070   Immunoglobulin heavy constant gamma 1\
                                                                (G1m marker)

  IMGSp9027F0514D   3                118471         Hs.15951    Proline-rich acidic protein 1

  IMGSp9027H0434D   2                BC044933       Hs.135094   Kinesin family member 18B

  IMGSp9027G0658D   2                BC010132       Hs.445893   KH domain containing, RNA binding, signal\
                                                                transduction- associated 1

  IMGSp9027F0369D   2                AK092483       Hs.470417   Penta-EF-hand domain containing 1

  IMGSp9027D1015D   2                NM_006814      Hs.471917   Proteasome (prosome, macropain) inhibitor\
                                                                subunit 1 (PI31)

  IMGSp9028C0313D   2                DA970556       Hs.510650   Clone IP80 immunoglobulin heavy chain\
                                                                variable region

  IMGSp9027G0525D   2                NM_002228      Hs.525704   Jun proto-oncogene

  IMGSp9027E0966D   2                BC041022       Hs.584909   SCAN domain containing 1

  IMGSp9027F0171D   2                BC018708       Hs.632706   Zinc finger CCCH-type containing 10

  IMGSp9027F0625D   2                BC018708       Hs.632706   Zinc finger CCCH-type containing 10

  IMGSp9028G0311D   2                BM920476       Hs.633485   Enhancer of polycomb homolog 1 (Drosophila)e

  IMGSp9028G027D    2                BX417981       Hs.698070   Immunoglobulin heavy constant gamma 1\
                                                                (G1m marker)

  IMGSp9028F099D    2                BG754662       Hs.698202   UniGene entry Hs.698202 has been retired;\
                                                                current entry: Transcribed locus, moderately\
                                                                similar to XP_001496515.2 PREDICTED: ig\
                                                                gamma-3 chain C region \[Equus caballus\]

  IMGSp9027H0728D   1                NM_001978      Hs.106124   Erythrocyte membrane protein band 4.9 (dematin)

  IMGSp9027C0116D   1                NM_080881      Hs.130316   Drebrin 1

  IMGSp9027D129D    1                NM_001012426   Hs.131436   Homo sapiens forkhead box P4 (FOXP4),\
                                                                transcript variant 1, mRNA

  IMGSp9027G0310D   1                BX647115       Hs.173381   Dihydropyrimidinase-like 2

  IMGSp9027G0172D   1                AF479827       Hs.182081   BR serine/threonine kinase 1

  IMGSp9028E0623D   1                NM_022489      Hs.24956    Inverted formin, FH2 and WH2 domain\
                                                                containing

  IMGSp9027C0164D   1                BC000786       Hs.25584    ADP-ribosylation factor GTPase activating\
                                                                protein 1

  IMGSp9027A0339D   1                BC008343       Hs.292493   X-ray repair complementing defective repair in\
                                                                Chinese hamster cells 6

  IMGSp9027C1211D   1                BC000459       Hs.306791   Polymerase (DNA directed), delta 2, accessory\
                                                                subunit

  IMGSp9027E0916D   1                BC040880       Hs.315568   Chromosome 10 open reading frame 114

  IMGSp9027H0366D   1                NM_003260      Hs.332173   Transducin-like enhancer of split 2 (E(sp1)\
                                                                homolog, Drosophila)

  IMGSp9028A0867D   1                AL833379       Hs.333388   Eukaryotic translation elongation factor 1 delta\
                                                                (guanine nucleotide exchange protein)

  IMGSp9027F1049D   1                NM_006548      Hs.35354    Insulin-like growth factor 2 mRNA binding\
                                                                protein 2

  IMGSp9027G1059D   1                AK097073       Hs.361323   ATP-binding cassette, sub-family F (GCN20),\
                                                                member 3

  IMGSp9027H0825D   1                AK127401       Hs.407368   LSM14A, SCD6 homolog A (S. cerevisiae)

  IMGSp9028A0819D   1                BC036307       Hs.465929   Calponin 1, basic, smooth muscle

  IMGSp9027D1063D   1                BC146654       Hs.493796   RUN and SH3 domain containing 2

  IMGSp9028D0712D   1                BC022890       Hs.511149   Synaptosomal-associated protein, 23kDa

  IMGSp9027F0118D   1                NM_002087      Hs.514220   Granulin

  IMGSp9027B0725D   1                NM_032627      Hs.515259   Single stranded DNA binding protein 4

  IMGSp9027G1020D   1                AK127255       Hs.515364   Rho GTPase activating protein 33

  IMGSp9027F0926D   1                BC090883       Hs.516160   Splicing factor 3b, subunit 4, 49kDa

  IMGSp9027H0318D   1                NM_003768      Hs.517216   Phosphoprotein enriched in astrocytes 15

  IMGSp9027B0425D   1                AB002328       Hs.517478   Calcineurin binding protein 1

  IMGSp9027D0732D   1                AK096320       Hs.517543   Pescadillo ribosomal biogenesis factor 1

  IMGSp9027E0219D   1                NM_015695      Hs.520096   Bromodomain and PHD finger containing, 3

  IMGSp9027B0369D   1                NM_007371      Hs.522472   Bromodomain containing 3

  IMGSp9027H1010D   1                NM_014866      Hs.522500   SEC16 homolog A (S. cerevisiae)

  IMGSp9027B0757D   1                NM_031372      Hs.527105   Heterogeneous nuclear ribonucleoprotein D-like

  IMGSp9027C0965D   1                NM_014811      Hs.533260   Protein phosphatase 1, regulatory subunit 26

  IMGSp9027E0964D   1                NM_001098800   Hs.571729   Melanoma antigen family D, 4

  IMGSp9027G0156D   1                BC037307       Hs.590990   Anoctamin 8

  IMGSp9027C1216D   1                AB208876       Hs.592082   Axin 1

  IMGSp9027F0322D   1                BF110897       Hs.612694   Transcribed locus

  IMGSp9027E0122D   1                BC004352       Hs.613351   Kinesin family member 22

  IMGSp9027G0312D   1                AK225632       Hs.631593   Protein phosphatase 1, regulatory subunit 15A

  IMGSp9027E104D    1                AL133055       Hs.636446   Zinc finger protein 853

  IMGSp9027A1171D   1                NM_032329      Hs.645460   Inhibitor of growth family, member 5

  IMGSp9027B0415D   1                XR_015693      Hs.654404   Major histocompatibility complex, class I, B

  IMGSp9027A0861D   1                BC006105       Hs.654798   Alpha tubulin acetyltransferase 1

  IMGSp9027F0471D   1                NM_002140      Hs.695973   Heterogeneous nuclear ribonucleoprotein K

  IMGSp9027D0731D   1                NM_001270      Hs.696018   Chromodomain helicase DNA binding protein 1

  IMGSp9027B0439D   1                AK124880       Hs.696054   Protein phosphatase 1, regulatory subunit 18

  IMGSp9027C0140D   1                AB209272       Hs.76662    Zinc finger, DHHC-type containing 16

  IMGSp9027C1264D   1                CR606311       Hs.77100    General transcription factor IIE, polypeptide 2,\
                                                                beta 34kDa

  IMGSp9027E1075D   1                AK128584       Hs.79110    Nucleolin
  -----------------------------------------------------------------------------------------------------------------

The 61 identified proteins comprised of a wide range of human proteins, including immunoglobulins, as well as a variety of nuclear, cytoplasmic and cell-membrane proteins with a diverse range of functions ( [Table 4](#T4){ref-type="table"}). In order to identify shared epitopes that could explain the observed antibody cross-reactivity, and to deduce the origin of the non-specific binding to either of the two tested antibodies, we investigated sequence similarities between the human proteins and the immunogens used to produce the antibodies. We conducted a linear (BLAST) and a segmented (SIM) *in silico* sequence analysis of chicken IgY and rabbit IgG immunoglobulins against 61 array-identified human proteins as detailed in supplementary Table 1. In total, 5 proteins met the BLAST threshold criteria of E-values below 1 × 10 ^-10^, as well as the SIM threshold criteria of scores above 50. A further 9 proteins met the SIM threshold, but they did not meet the BLAST criteria ( [Table 5](#T5){ref-type="table"}).

All 5 proteins that met both threshold criteria belong to the immunoglobulin class of proteins, four being variable regions of Ig heavy chains and one a heavy constant gamma chain. The *in silico* sequence analysis revealed the highest sequence similarity to Ig heavy variable and constant chains, respectively, of both, the chicken IgY and rabbit IgG in all cases ( [Supplementary Table 1](#ST1){ref-type="other"}) making it impossible with this approach to deduce the origin of the cross-reactivity.

###### *In silico* sequence similarity analysis between chicken IgY and rabbit IgG and array-identified human proteins.

14 most similar human proteins detected in this study, prioritised by sequence similarity.

  ------------------------------------------------------------------------------------------------------------------------------------
  Human protein                     Chicken Immunoglobulins   Rabbit Immunoglobulins   Signal\                                     
                                                                                       Intensity                                   
  --------------------------------- ------------------------- ------------------------ ----------- ----- --- ----------- --- ----- ---
  Clone SFV019_2F0 5H\              1                         1.00E-48                 2           393   2   3.00E-47    4   356   3
  immunoglobulin heavy\                                                                                                            
  chain variable region                                                                                                            

  Clone IgA-MZ-aa42c-2\             1                         4.00E-30                 2           210   1   1.00E-29    1   194   3
  immunoglobulin alpha\                                                                                                            
  heavy chain variable region\                                                                                                     
  (IgA)                                                                                                                            

  IGH mRNA for\                     2                         2.00E-34                 1           218   1   1.00E-41    2   291   3
  immunoglobulin heavy\                                                                                                            
  chain VHDJ region, partial\                                                                                                      
  cds, clone:TRH1-16                                                                                                               

  Immunoglobulin heavy\             1                         3.00E-13                 1           86    2   2.00E-125   2   890   3
  constant gamma 1 (G1m\                                                                                                           
  marker)                                                                                                                          

  Clone IP80 immunoglobulin\        1                         3.00E-44                 1           313   1   3.00E-49    2   357   2
  heavy chain variable region                                                                                                      

  Enhancer of polycomb\             0                         BT                       1           51    0   BT          0   BT    2
  homolog 1 (Drosophila)e                                                                                                          

  Inverted formin, FH2 and\         0                         BT                       0           NA    0   BT          1   51    1
  WH2 domain containing                                                                                                            

  Chromosome 10 open\               0                         BT                       1           51    0   BT          0   BT    1
  reading frame 114                                                                                                                

  RUN and SH3 domain\               0                         BT                       1           52    0   BT          0   BT    1
  containing 2                                                                                                                     

  Single stranded DNA\              0                         BT                       1           56    0   BT          0   BT    1
  binding protein 4                                                                                                                

  Rho GTPase activating\            0                         BT                       1           54    0   BT          0   BT    1
  protein 33                                                                                                                       

  Splicing factor 3b, subunit 4,\   0                         BT                       1           61    0   BT          0   BT    1
  49kDa                                                                                                                            

  Protein phosphatase 1,\           0                         BT                       1           59    0   BT          0   BT    1
  regulatory subunit 26                                                                                                            

  Alpha tubulin\                    0                         BT                       1           50    0   BT          0   BT    1
  acetyltransferase 1                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------

'BT' signifies 'Below Threshold Value'. Threshold values were BLAST E-values below 1 × 10 ^-10^ and SIM values above 50. 'NA' signifies 'No significant similarity was detected'

^\*^BLAST and SIM overlaps indicate the number of sequence categories meeting threshold criteria for similarity as shown in [Supplementary Table 1](#ST1){ref-type="other"}.

The 9 proteins that met only the SIM threshold criteria belong to a wide range of protein classes, however, none of those proteins belongs to the immunoglobulin class of proteins. In silico sequence analysis revealed that 8 of those proteins have a high local sequence similarity to the chicken immunoglobulin Y heavy chain constant region, but not to any other chicken and rabbit Ig regions. The analysis revealed further, that Inverted Formin, FH2 and WH2 Domain Containing (INF2) showed high local similarity exclusively to the rabbit Ig gamma chain constant region ( [Supplementary Table 1](#ST1){ref-type="other"}).

Conclusion
==========

This work illustrates the cross-reactivity of an antibody-based detection system for IgY binding. The polyclonal anti-IgY rabbit antibody in combination with an anti-rabbit IgG alkaline phosphatase-conjugated antibody was shown to bind to 61 human proteins present on Unipex protein arrays comprising of 7,390 human proteins. Characterisation of this cross-reactivity provides a 'false-positive' database for future chicken antisera characterisation on protein array systems not limited to the Unipex protein array used here. These results, in combination with 'false-positives' from earlier research investigating antibody cross-reactivity by this group ^[@ref-12]^ and others ^[@ref-13]^ may provide valuable information for future protein array-based experiments. Reference lists provided by such experiments would be further strengthened by arrays that include additional portions of the human proteome and/or post-translational modifications. Using antibodies that have been extensively characterised on protein arrays will reduce the risk of identifying irrelevant cross-reactive secondary antibody binding to the array as a host-antigen response.

It is important to note that the current study was a one-off experiment and repeat experiments may increase the reliability of the data. The reproducibility of the binding events identified in this study was further warranted by evaluating each protein in two discrete positions on the array. Of the 63 binding events, five were scored as intensity 3, twelve were scored as intensity 2 and the remainder were intensity 1. While the assay is unable to conclusively distinguish the precise cause of the differences in signal intensities, it can be assumed to be due to variations in antibody affinity and avidity, the availability of the epitope for binding, and protein concentrations on the array. A follow-up quantitative Western blot analyses and titration experiments would help further to shed more light into differences in antigen-binding kinetics.

The secondary antibodies utilized in this study are polyclonal, isolated by immunoaffinity chromatography. The presented cross-reactivity reference list may, therefore, show some variation when a different lot of the antibody is used. We have previously shown that conditions applied during affinity chromatography may affect specificity ^[@ref-14]^. When assessing protein array images, we found a considerable discrepancy in background intensity of array part 1 and 2. It is important to highlight that the part 1 and part 2 of the array are generated from distinct clone libraries of different tissue origin. Part 1 of the array was generated from human brain tissue using a pQE30NST vector, whereas part 2 of the array was generated from different sources of tissue, including T cells and lung tissue, using a pQE80LSN vector. The tissue origin and the utilised bacterial vector are potential contributing factors for the variances in background noise.

Since both antibodies were used as a pair in this study, it was not possible to directly deduce the exact cross-reactivity profile for each individual antibody. We have therefore taken an *in silico* sequence analysis approach and we found that five of the identified proteins were of the immunoglobulin class of proteins with very high sequence similarities to both, the chicken IgY and the rabbit IgG immunoglobulins. Such cross-reactivity is not surprising considering that the antibodies are polyclonal and the immunogens were immunoglobulins of both hosts. In addition, the data sheet provided with the anti-chicken IgY antibody produced in rabbit (31104, Thermo Fisher) has specified that this antibody may cross-react with immunoglobulins from other species. The data sheet for the goat anti-rabbit IgG AP antibody (A3687, Sigma-Aldrich) has specified binding to all rabbit immunoglobulins. The *in silico* sequence analysis revealed furthermore 8 proteins with high sequence similarity to chicken IgY heavy chain constant region and one protein with high sequence similarity to rabbit Ig gamma chain constant region. In order to tackle this issue experimentally, a single labelled antibody should be tested on its own in future experiments. Furthermore, if a non-labelled antibody is to be tested, two experiments should be performed, one with a labelled and non-labelled antibody pair such as demonstrated in this study, and one additional experiment with the labelled antibody alone, thereby allowing allocation of exact cross-reactivates by simply subtracting 'false-positives' from both sets of results.

In conclusion, the antibodies tested in this study showed cross-reactivity to unrelated human proteins as well as to human immunoglobulin proteins, which are homologous to the original immunogens. Despite the identified non-specific binding, the tested antibodies are suitable for use in protein array experiments as the cross-reactive binding partners can be readily excluded from further analysis. As both antibodies were used as a pair in this study, the possibility to deduce the exact cross-reactivity profile for each individual antibody may be limited. However, the cross-reactivity reference list provided in this paper can be further utilised to validate research using those antibodies in applications other than protein arrays.

Supplementary material {#SM1}
======================

Click here for additional data file. In order to investigate whether potential shared epitopes exist between immunogens (chicken IgY, rabbit IgG) used to produce the secondary antibodies tested in this study and the human proteins bound non-specifically by those secondary antibodies on protein arrays, we analysed sequence similarities using BLASTP and the local similarity program SIM. We used sequences of protein IDs provided by the Unipex protein database and compared those to chicken and rabbit immunoglobulin proteins (Methods section, Epitope analysis). The [Table S1](#ST1){ref-type="other"} shows the results for all possible two-pair sequence alignment combinations presented as BLAST scores, E-values and SIM scores.

Click here for additional data file. Original image of protein array (Number 633.4.730) probed with rabbit anti-chicken IgY and alkaline phosphatase-conjugated goat anti-rabbit IgG, visualised using AttoPhos AP Fluorescent Substrate.

Click here for additional data file. Original image of protein array (Number 634.5.737) probed with rabbit anti-chicken IgY and alkaline phosphatase-conjugated goat anti-rabbit IgG, visualised using AttoPhos AP Fluorescent Substrate.

Click here for additional data file. Cross-reactive proteins listed in [Table 4](#T4){ref-type="table"} are highlighted corresponding to their intensity as red (intensity 3 = strong), green (intensity 2 = intermediate) and yellow (intensity 1 = weak) circles.

Click here for additional data file. Cross-reactive proteins listed in [Table 4](#T4){ref-type="table"} are highlighted corresponding to their intensity as red (intensity 3 = strong), green (intensity 2 = intermediate) and yellow (intensity 1 = weak) circles.
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The authors have improved their manuscript considerably. The last sentence of the Introduction needs correction. Otherwise, the paper has been sufficiently improved for publication.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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In the present work, the authors have tested direct binding of secondary antibodies to arrays of human proteins.

Readers who use array technology may benefit from the present work, since they will become aware of the problem of signals caused by secondary antibodies and not by the primary antibody. It appears that human immunoglobulins are frequently detected by secondary antibodies, which is a useful finding that would likely also be relevant for other secondary antibodies.

The authors have included the original images in the supplement, which is useful for users of the technique.

**Issues** In the Results section, it should be made clear that the arrays were probed with both antibodies in the same experiment, not one antibody at a time.It would be interesting how strong the signals caused by the secondary antibodies are in comparison to signals obtained in the presence of a primary antibody.In comparison, the part 1 image has a much higher background than part 2. It appears that very clear signals were obtained from part 2, but not from part 1. In the part 1 image, there is considerable background and almost all positions have been slightly stained. I would recommend repeating the experiment to verify whether the weak signals obtained on part 1 can be reproduced.Two secondary antibodies were used in the same experiment. Therefore, it cannot be determined which of the two antibodies gave rise to the signals on the array. This problem should be discussed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Kijanka

Gregor

Dublin City University, Ireland
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The authors would like to thank Dr. Konrad Büssow for his thorough review of this article and his helpful comments. Dr. Büssow points out that the authors should stress that both secondary antibodies were used in the same experiment using one single set of protein arrays. This experimental design issue entails that it cannot be determined which signals are caused by which antibody. We have highlighted and discussed both issues throughout the text and we performed an additional sequence analysis in an *in silico*approach to clarify the origin of the signals on the protein array. The results of these analyses are presented in the new Table 5 and Supplementary table 1 and are further discussed in the text.

Dr. Büssow has furthermore highlighted the differences in background signal between the two arrays of the protein array set. The authors have encountered similar background differences when using other sets of antibodies and serum samples and find similar discrepancies in background noise being likely due to different tissues and vectors used for the generation of the distinct expression clone libraries utilized for array 1 and 2. This issue is now specifically highlighted in the article.
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This article describes an experiment performed to characterize the background signals in a particular combination of three commercially available research tools: a protein macroarray on PVDF membranes used in conjunction with two antibodies used for detection. As no first antibody or serum was used in this experiment, all the signals could be attributed to unwanted, unspecific reactivity of the detection antibody combination used. A list of genes was generated from these signals that is proposed as a reference database of for other researchers.

In general, the approach is scientifically sound and feasible. Background reactivities may limit antibody-based assays and need to be accounted for. So performing a control experiment without serum or first antibody on a protein array and with just the detection antibodies makes perfectly sense to control for unspecific binding. The title of the paper is appropriate, the abstract gives enough information on the setting. The background information about the antibodies is described in enough detail. However, the narrow focus of the paper and a number of technical issues limit the quality of the paper and its utility for the readership.

**Major issues** The experiment was performed only once. Consequently, the reliability of the results will be limited.Only one specific combination of a protein macroarray with two consecutive detection antibodies was analyzed. It remains unclear, whether the results obtained would apply to other lots of the antibodies or whether they are specific for a certain preparation, limiting the benefit of this protein list as a reference database and also limiting the replication of results by other groups.The authors suggest that their results may also apply to other protein array systems. This claim needs substantiation, especially in the case of *E.coli* proteins derived from high-throughput cloning that do not show authentic posttranslational modification patterns and often contain extra amino acid sequences that may cause unspecific binding.The paper discusses cross-reactivity with human Ig genes. A sequence analysis of the other cross-reactive proteins with IgY and rabbit Ig sequences may provide evidence for the mechanisms behind this phenomenon, expanding scope and depth of this so far rather descriptive study.

**Minor issues** Antibody concentrations should be given explicitly, e.g. as µg/ml rather than as dilutions.The procedure of signal quantification and scoring needs to be described in more detail. The description states \"Positive signals were localized according to the manufacturer's protocol\" - what exactly was done to identify positive signals? The pictures provided show varying background intensities as well as a number of very dark spots that do not appear in the analysis. Which algorithm was used to include or exclude signals? How were the different signal intensities attributed to the score values 1, 2 and 3?It would be interesting to know why this specific combination of two detection antibodies was used here: a polyclonal anti-chicken IgY antibody produced in rabbit and then a polyclonal goat anti-rabbit IgG antibody conjugated with alkaline phosphatase. Was there no conjugated anti-chicken antibody available? Every additional antibody will add to the number of unspecific reactions, so using just one instead of two may help reduce background.The abstract does not provide a conclusion on whether the antibodies should be used in a particular setting (see Article Guidelines For Antibody Validation Articles).

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Kijanka
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The authors would like to thank Dr. Carsten Grötzinger for his very helpful observations which prompted us to perform additional *in silico* analysis resulting in an improvement of this paper. Dr Grötzinger points out that the paper has its limitations due to the fact that only one experiment has been performed leading to questions regarding reliability of data, lot-to-lot reproducibility and combinations of antibody pairs. As those issues are certainly important, however, not feasible to address in this specialized antibody validation paper, we have discussed those within the text; For instance, the lot-to-lot reproducibility of polyclonal antibodies is an important issue that needs to be taken into consideration during the experimental design of a study, it goes however, beyond the scope of this particular article. The important issue of determining the origin of the identified signals to either of the secondary antibodies tested in a single protein array experiment is now, however, addressed in more detail. We have performed an additional *in silico* analysis comparing sequence similarities between the antibody immunogens used to produce the secondary antibodies and the human proteins identified on the arrays. The analysis shed some light into the possibility that all immunoglobulin (Ig) related signals were caused by both tested secondary antibodies and others were caused by either of the two antibodies. These findings are particularly interesting, as the binding patterns of the non-labelled secondary antibody are difficult to show unless additional labelling is performed directly on the antibody. Such additional labelling might, however, impact on the antibody binding specificity. The results of those analyses, as discussed in a similar manner in the Reviewer 1 response, are presented in a new Table 5 and Supplementary Table 1 and further discussed in the text.

The authors have also addressed miner issues related to post-translational modification, antibody concentrations, signal quantification and others throughout the text.

In addition, we concluded that the antibodies should be used in a particular setting and highlighted this in the abstract as required in the Article Guidelines For Antibody Validation Articles.

10.5256/f1000research.8257.r12247

Referee response for version 1

Hantusch

Brigitte

1

Referee

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

**Competing interests:**No competing interests were disclosed.

3

2

2016

Version 1

This study presents data concerning the issue of secondary antibody cross-reactivity towards antigens other than desired immunoglobulins. By screening a high-throughput protein array, the authors establish the amount and identity of proteins detected by commercially available secondary antibodies, a rabbit anti-chicken antibody combined with an AP-conjugated goat anti-rabbit antibody.

**Title and Abstract**: The title might contain the information that [two]{.ul} detection antibodies were used. The abstract represents a sound summary of the work performed.

**Article:** The methods used are described clearly, especially by showing a concise work flow as seen in table 3.

**Data:** Results are described appropriate and sufficiently. Supplementary Figures S1 and S2 have very huge size and are dispensable. The sentence about signal intensity differences due to varying protein amounts should be part of the conclusion section and also discussed more extensively.

**Conclusion**: The conclusions drawn are appropriate and concise. Briefly can some information be drawn from the kind / category of proteins falsely detected?

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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The authors would like to thank Dr. Brigitte Hantusch for kindly reviewing this manuscript and the helpful and detailed comments. We have discussed the signal intensity differences in more detail in the text as highlighted by Dr. Hantusch. We decided to retain the current title of the article as it points to a more general applicability of our validation approach to other antibodies.

Furthermore, we have extensively addressed Dr. Hantusch comments regarding categories of proteins detected on the protein array as part of the new *in silico* analysis as presented in Table 5 and in the supplementary Table 1

[^1]: ROK and GSK designed the study, DL performed the protein array experiments and GSK conducted data analysis. GSK conceived and DL performed *in silico* sequence analyses. GSK wrote and DL and ROK critically reviewed and edited the article. All authors have agreed to the final content of the manuscript.

[^2]: **Competing interests:**The authors do not declare any competing interests.
